ImmuCell Corporation ICCC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +66.83%
- 1 year
- +68.47%
- Open
- 10.25
- Prev close
- 10.54
- Mkt cap
- 93.18M
- Vol
- 11.02K
- Avg vol
- 18.05K
- EPS
- 0.07
- P/E
- 146.57
- Div yield
- 0.00%
More statistics
- Low
- 9.98
- High
- 10.36
- Forward P/E
- -42.82
- Beta
- 0.57
- Short ratio
- 0.23
- Inst. own
- 14.51%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.93
- 200-d avg
- 4.28
- 1y target
- 0.00
6M chart
Signals (23)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 29, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 27, 2026 | 5 days ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 18, 2026 | 5 months ago |
| RSI: Overbought | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
Key statistics
- Market cap
- 41.97M
- Enterprise value
- 42.71M
- Trailing P/E
- 0.00
- Forward P/E
- -42.82
- PEG ratio
- 0.00
- Price / sales
- 1.81
- Price / book
- 1.46
- EPS (TTM)
- -0.49
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -17.44%
- Revenue (TTM)
- 23.22M
- Revenue growth
- 54.90%
- Free cash flow
- 522.36K
- Total cash
- 1.32M
- Total debt
- 15.84M
- Return on equity
- -16.10%
- Shares outstanding
- 8.91M
- Short % of float
- 0.06%
- 50-day average
- 3.93
- 200-day average
- 4.28
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.09 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.20 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.06 | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | -0.15 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.12 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.18 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | init | — | Buy |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immucell.com
News
- ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
- ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript
- ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY
- ImmuCell Q2 Total Product Sales Rises 12%
- ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY
- Earnings Scheduled For May 14, 2026
- ImmuCell And Norbrook Laboratories Reach Settlement Agreement, Norbrook To Pay $2M Following Expiration Of 2019 Supply Deal
- ImmuCell Reports Q1 Preliminary Sales $10.4M Up From 28.4% YoY
- ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY
- Earnings Scheduled For March 4, 2026
Your note
Sign in to keep a note on ICCC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cresset Asset Management, LLC | 2.96% | 264,002 | 1.24M | Sep 29, 2024 |
| Vanguard Group Inc | 2.53% | 225,595 | 1.06M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.68% | 149,489 | 704.09K | Sep 29, 2024 |
| Bleichroeder LP | 1.14% | 101,594 | 478.51K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.82% | 72,682 | 342.33K | Sep 29, 2024 |
| Morgan Stanley | 0.71% | 63,516 | 299.16K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.78% | 158,957 | 748.69K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 66,638 | 313.86K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 29,102 | 137.07K | Oct 30, 2024 |
| DFA U.S. Small Cap Value Series | 0.32% | 28,578 | 134.60K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 13,747 | 64.75K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 13,127 | 61.83K | Oct 30, 2024 |